cervical cancer vaccine
| 4:52PM 1/14/2010
Merck shares rose more than 6% in two days as investors reacted to an analyst's upgrade and news that the drugmaker is trying to broaden the market for its human papillomavirus/cervical cancer vaccine, Gardasil.